Physician profile
Amy Macintyre
NPI 1609035260
$2,251.30
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $73.17 · 2021: $184 · 2022: $172 · 2023: $252 · 2024: $632 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $468.38 | 2022-2025 | Azstarys |
| Abbvie INC. | $300.50 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.47 | 2021-2025 | Caplyta |
| Lundbeck LLC | $194.98 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $123.45 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $122.63 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $91.10 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $83.60 | 2019-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $77.62 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $66.08 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $60.21 | 2019 | |
| Alkermes, INC. | $51.97 | 2023-2025 | Aristada, Lybalvi |
| Shire North American Group INC | $51.03 | 2019 | |
| Axsome Therapeutics, INC. | $45.10 | 2023-2024 | Auvelity |
| Neos Therapeutics, Lp | $37.75 | 2024 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $32.03 | 2024 | Xelstrym |
| Neurocrine Biosciences, INC. | $30.29 | 2025 | |
| Allergan, INC. | $29.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.89 | 2019 | |
| Adlon Therapeutics L.P. | $25.33 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $23.39 | 2019 | |
| Neuronetics, INC. | $17.59 | 2019 | |
| Tris Pharma INC | $13.89 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Macintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.